SGLT2 inhibitors may be a better treatment option for some older, frail patients hospitalized with heart failure, according to a study presented at the 2025 annual meeting of the Heart Failure Society ...

Phenotyping in HFpEF aids in tailoring therapies, addressing comorbidities, and improving patient outcomes. Artificial intelligence models effectively diagnose HFpEF and predict mortality, enhancing ...

For decades, physicians had little to offer patients who have heart failure with preserved ejection fraction (HFpEF), which is a growing global health problem with a grim death rate in the 5 years ...

LONDON -- The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) improved outcomes driven by soft endpoints in patients with heart failure and mildly reduced or preserved ...

Finerenone reduced heart failure (HF) events and cardiovascular death in patients with HF and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), according to late-breaking research ...